Position in LXEO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$28,700,000
-$20,950,000 QoQ
Shares Held
5,000,000
0.0% QoQ
Ownership
6.37%
of shares outstanding
% of Portfolio
0.30%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LXEO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026RA CAPITAL MANAGEMENT, L.P. holds $9,134,713,488 across 74 Biotechnology names. LXEO ranks #45 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
10,281,496 | $2,351,686,580 | |
| 2 | PCVX |
Vaxcyte, Inc.
|
11,474,599 | $666,788,947 | |
| 3 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
6,666,837 | $579,814,813 | |
| 4 | TYRA |
Tyra Biosciences, Inc.
|
12,198,625 | $467,207,337 | |
| 5 | SION |
Sionna Therapeutics, Inc.
|
9,905,045 | $397,093,254 | |
| 6 | EWTX |
Edgewise Therapeutics, Inc.
|
10,428,437 | $328,495,765 | |
| 7 | NAMS |
NewAmsterdam Pharma Co N.V.
|
9,550,191 | $305,701,613 | |
| 8 | NUVL |
Nuvalent, Inc.
|
2,534,145 | $259,623,155 |
All Filings in LXEO
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $28,700,000 | 5,000,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $49,650,000 | 5,000,000 | Shares | Sole | 2026-02-17 | |
| 2025-10-20 | $46,100,000 | 5,000,000 | Shares | Sole | 2025-10-27 | |
| 2025-03-31 | $1,896,542 | 546,554 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $3,596,325 | 546,554 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $4,940,848 | 546,554 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $10,790,300 | 672,712 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||